196 related articles for article (PubMed ID: 33048385)
1. Induction immunosuppression and the risk of incident malignancies among older and younger kidney transplant recipients: A prospective cohort study.
Wang L; Motter J; Bae S; Ahn JB; Kanakry JA; Jackson J; Schnitzler MA; Hess G; Lentine KL; Stuart EA; Segev DL; McAdams-DeMarco M
Clin Transplant; 2020 Dec; 34(12):e14121. PubMed ID: 33048385
[TBL] [Abstract][Full Text] [Related]
2. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
3. Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab.
Pham C; Kuten SA; Knight RJ; Nguyen DT; Graviss EA; Gaber AO
Transpl Infect Dis; 2020 Jun; 22(3):e13257. PubMed ID: 32031729
[TBL] [Abstract][Full Text] [Related]
4. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
[TBL] [Abstract][Full Text] [Related]
5. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
Wang W; Yin H; Li XB; Hu XP; Yang XY; Liu H; Ren L; Wang Y; Zhang XD
Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
[TBL] [Abstract][Full Text] [Related]
6. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
[TBL] [Abstract][Full Text] [Related]
7. Lack of Benefit and Potential Harm of Induction Therapy in Simultaneous Liver-Kidney Transplants.
AbdulRahim N; Anderson L; Kotla S; Liu H; Ariyamuthu VK; Ghanta M; MacConmara M; Tujios SR; Mufti A; Mohan S; Marrero JA; Vagefi PA; Tanriover B
Liver Transpl; 2019 Mar; 25(3):411-424. PubMed ID: 30506870
[TBL] [Abstract][Full Text] [Related]
8. Induction immunosuppression agents as risk factors for incident cardiovascular events and mortality after kidney transplantation.
Sandal S; Bae S; McAdams-DeMarco M; Massie AB; Lentine KL; Cantarovich M; Segev DL
Am J Transplant; 2019 Apr; 19(4):1150-1159. PubMed ID: 30372596
[TBL] [Abstract][Full Text] [Related]
9. Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus.
Kucirka LM; Durand CM; Bae S; Avery RK; Locke JE; Orandi BJ; McAdams-DeMarco M; Grams ME; Segev DL
Am J Transplant; 2016 Aug; 16(8):2368-76. PubMed ID: 27111897
[TBL] [Abstract][Full Text] [Related]
10. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
11. Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis.
Ali H; Soliman KM; Shaheen I; Kim JJ; Kossi ME; Sharma A; Pararajasingam R; Halawa A
Int Urol Nephrol; 2020 Apr; 52(4):791-802. PubMed ID: 32170593
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.
Peng W; Liu G; Xie W; Huang H; Wu J; Shou Z; Chen J
Int J Clin Pract Suppl; 2015 May; (183):23-8. PubMed ID: 26177071
[TBL] [Abstract][Full Text] [Related]
13. Induction Therapy in Elderly Kidney Transplant Recipients With Low Immunological Risk.
Masset C; Boucquemont J; Garandeau C; Buron F; Morelon E; Girerd S; Ladrière M; Mourad G; Garrigue V; Cassuto E; Albano L; Foucher Y; Dantal J;
Transplantation; 2020 Mar; 104(3):613-622. PubMed ID: 31283665
[TBL] [Abstract][Full Text] [Related]
14. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
[TBL] [Abstract][Full Text] [Related]
15. Impact of antibody induction on the outcomes of new onset diabetes after kidney transplantation: a registry analysis.
Santos AH; Leghrouz MA; Bueno EP; Andreoni KA
Int Urol Nephrol; 2022 Mar; 54(3):637-646. PubMed ID: 34216339
[TBL] [Abstract][Full Text] [Related]
16. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
17. The Influence of Antithymocyte Globulin Dose on the Incidence of CMV Infection in High-risk Kidney Transplant Recipients Without Pharmacological Prophylaxis.
de Paula MI; Bae S; Shaffer AA; Garonzik-Wang J; Felipe CR; Cristelli MP; Waldram MM; Massie AB; Medina-Pestana J; Segev DL; Tedesco-Silva H
Transplantation; 2020 Oct; 104(10):2139-2147. PubMed ID: 31978003
[TBL] [Abstract][Full Text] [Related]
18. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.
Sureshkumar KK; Thai NL; Hussain SM; Ko TY; Marcus RJ
Transplantation; 2012 Apr; 93(8):799-805. PubMed ID: 22290269
[TBL] [Abstract][Full Text] [Related]
19. Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era.
Amin AA; Araj FG; Ariyamuthu VK; Drazner MH; Ayvaci MUS; Mammen PPA; Mete M; Urey MA; Tanriover B
Clin Transplant; 2019 Aug; 33(8):e13651. PubMed ID: 31230375
[TBL] [Abstract][Full Text] [Related]
20. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
